Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease
BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …
Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More